- Home
- OMER vs SDA Comparison
OMER vs SDA Comparison
Compare OMER & SDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- SDA
- Stock Information
- Founded
- OMER 1994
- SDA 2007
- Country
- OMER United States
- SDA China
- Employees
- OMER N/A
- SDA N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- SDA Blank Checks
- Sector
- OMER Health Care
- SDA Finance
- Exchange
- OMER Nasdaq
- SDA Nasdaq
- Market Cap
- OMER 274.3M
- SDA 265.8M
- IPO Year
- OMER 2009
- SDA N/A
- Fundamental
- Price
- OMER $7.61
- SDA $1.96
- Analyst Decision
- OMER Strong Buy
- SDA Buy
- Analyst Count
- OMER 6
- SDA 1
- Target Price
- OMER $27.50
- SDA $3.50
- AVG Volume (30 Days)
- OMER 8.1M
- SDA 103.3K
- Earning Date
- OMER 11-12-2025
- SDA 11-18-2025
- Dividend Yield
- OMER N/A
- SDA N/A
- EPS Growth
- OMER N/A
- SDA N/A
- EPS
- OMER N/A
- SDA N/A
- Revenue
- OMER N/A
- SDA $458,905,000.00
- Revenue This Year
- OMER N/A
- SDA $20.77
- Revenue Next Year
- OMER N/A
- SDA $19.32
- P/E Ratio
- OMER N/A
- SDA N/A
- Revenue Growth
- OMER N/A
- SDA 24.15
- 52 Week Low
- OMER $2.95
- SDA $1.86
- 52 Week High
- OMER $13.60
- SDA $11.28
- Technical
- Relative Strength Index (RSI)
- OMER 62.09
- SDA 36.00
- Support Level
- OMER $7.43
- SDA $1.86
- Resistance Level
- OMER $12.10
- SDA $2.43
- Average True Range (ATR)
- OMER 0.69
- SDA 0.16
- MACD
- OMER 0.17
- SDA -0.02
- Stochastic Oscillator
- OMER 44.09
- SDA 24.14
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.